GLP-1s are evolving — how benefit managers can prepare

Published Updated 5 Min Read

Hand holding white pill, pink background
Adobe Stock

Breakthroughs in weight loss medication keep coming, which means it’s only a matter of time before employees ask about new or updated coverage. But shedding pounds and keeping them off requires more than medicine.

One of the latest GLP-1 advancements is Eli Lilly’s new oral obesity drug, Orforglipron, which during testing helped reduce weight and blood sugar levels in type 2 diabetes patients, with effectiveness on par with popular injectible weight loss drugs such as Ozempic and Wegovy. 

Lee Hafner
Editor

Lee joined the EBN team in 2022, and covers areas including caregiving, employee health and wellness, healthcare innovation, and company culture. She created EBN's popular Benefits in Action and … Read full bio


For reprint and licensing requests for this article, click here.


More From Employee Benefit News

Sign Up Form

Login Modal Form